While the risk of EBV post-transplant lymphoproliferative disease (PTLD) is reduced by depletion of CD19+ B cells, CD3/CD19-depleted grafts also seem to facilitate engraftment and to support the graft-versus-leukemia/tumor (GvL/T) effect (9). This evidence concerns the gene CD19 and post-transplant lymphoproliferative disease.